MTORC1 hyperactivation in lymphangioleiomyomatosis leads to ACE2 upregulation in type II pneumocytes: implications for COVID-19. Issue 2 (11th February 2021)

• Record Type: Journal Article
• Authors: Tang, Yan; Kwiatkowski, David J.; Henske, Elizabeth P.
• Is Part Of: European respiratory journal. Volume 57:Issue 2(2021)
• Publication Date: 2021-02-11
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.02737-2020
• Languages: English
• ISSNs: 0903-1936

Abstract

Respiratory failure is among the gravest outcomes of coronavirus disease 2019 (COVID-19), and most of the severe cases are associated with significant lung comorbidities [1]. Lymphangioleiomyomatosis (LAM) is a progressive cystic lung disease of women caused by mutations in tuberous sclerosis genes, resulting in aberrant hyperactivation of the mTOR complex 1 (mTORC1) signalling network in LAM cells, which are of mesenchymal origin [2]. The risk of COVID-19 in LAM is unknown. Increased pneumocyte expression of the SARS-CoV-2 entry receptor ACE2 in lymphangioleiomyomatosis (LAM) is associated with upregulation of interferon pathways in natural killer cells as well as increased IL6 expression in LAM-associated fibroblasts https://bit.ly/34ChSsg